Skip to main content

Table 1 Demographic and Clinical Characteristics at Baseline

From: Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder

  Placebo N = 116 IR-MPH (tid) N = 102 OROS-MPH N = 67  
  mean ± sd/N (%) mean ± sd/N (%) mean ± sd/N (%) Omnibus Statistic
Age (years) 38.5 ± 9.1 35.7 ± 9.8 32.7 ± 18.5 * F(2,282) = 5.0, p = 0.007
Sex (male) 58 (50) 60 (59) 38 (57) χ2 (2) = 1.8, p = 0.4
Weight (kg) 82.9 ± 18.9 79.9 ± 15.8 84.1 ± 20.1 F(2,282) = 1.3, p = 0.3
ADHD     
   Onset (years) 5.0 ± 2.9 6.3 ± 6.7 5.2 ± 2.2 F(2,253) = 2.0, p = 0.1
   Symptoms (lifetime) 14.3 ± 2.8 13.5 ± 3.4 14.4 ± 2.7 F(2,248) = 4.3, p = 0.1
   Symptoms (Current) 12.1 ± 3.7 11.5 ± 3.9 12.2 ± 2.9 F(2,248) = 2.0, p = 0.4
CGI Severity     
   Mild 1 (1) 1 (1) 1 (1) χ2 (6) = 9.6, p = 0.1
   Moderate 52 (45) 31 (30) 27 (40)  
   Marked 53 (46) 60 (59) 38 (57)  
   Severe 10 (9) 10 (10) 1 (1)  
GAF     
   Past (worst) 52.2 ± 5.6 52.3 ± 5.9 51.4 ± 4.7 F(2,259) = 0.6, p = 0.5
   Current 59.0 ± 4.9 59.9 ± 5.0 57.8 ± 4.2$ F(2,259) = 4.1, p = 0.02
HAM-A 4.6 ± 3.9 5.8 ± 4.8 4.4 ± 3.8 F(2,281) = 3.2, p = 0.04
HAM-D 4.4 ± 4.5 5.1 ± 5.3 4.8 ± 4.7 F(2.282) = 0.6, p = 0.6
  1. *, p < 0.05 versus Placebo, $, p < 0.05 versus IR-MPH (tid).